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Abstract
 .The expression and signal transduction of the glucagon receptor GR have been studied in b TC3 cells. Northern blot
and RT-PCR analysis indicated the expression of the GR gene in b TC3 cells. One-5 nM glucagon stimulated a 2.5-fold
increase in the IP production. At glucagon concentrations higher than 5 nM, the production of IP was blunted but nots s
abolished. The accumulation of intracellular cAMP was observed following the stimulation with 5 nM of glucagon. A
maximal 4.5-fold increase in cAMP was observed using 250 nM glucagon and higher. Comparative studies using a
1w x9glucagon anatogonist, des-His Glu glucagon, showed no effect on intracellular cAMP and IPs in b TC3 cells. Our data
shows that the GR gene is expressed in b TC3 cells. The GR in b TC3 cells transmits its intracellular signal by causing the
accumulation of both IP and cAMP.s
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1. Introduction
Glucagon is a twenty nine amino acid hormone
that plays an important role in the regulation of
glucose homeostasis and the pathogenesis of diabetes
w x1 . The main target organ of glucagon action is the
w xliver 1 . Glucagon functions to maintain basal glu-
cose level by activating two enzymatic pathways in
w xthe liver, glycogenlysis and gluconeogenesis 2 . In
pancreatic islets, glucagon acts as an insulin secreta-
w xgogue 3 . It has been shown using rat hepatocytes
that glucagon can activate adenylate cyclase by a
w xGs-mediated process 4,5 . In addition, glucagon can
also elicit a rapid, transient increase in hepatic protein
) Corresponding author. Fax: q1 718 4308565; E-mail: char-
ron@aecom.yu.edu
w xkinase C and phospholipase C activity 4–8 . Two
populations of hepatic glucagon receptors have been
proposed based upon both binding and functional
w xstudies 9–12 .
The glucagon receptor cDNA has been cloned
w xfrom rat, human and mouse liver 13–15 . The cDNA
is approximately 1.9kb and it encodes a polypeptide
of 485 amino acids. The glucagon receptor is approx-
imately 55kDa and contains four potential N-linked
w xglycosylation sites 13 . Sequence comparisons have
shown that the glucagon receptor belongs to a family
of hormone receptors specific for intermediate-sized
peptides such as glucagon like peptide-1, calcitonin,
parathyroid hormone and parathyroid hormone-re-
w xlated peptide 13 . All members of this receptor sub-
family are predicted to have seven transmembrane
w xdomains 13 . Transfection of the rat hepatic glucagon
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receptor cDNA into BHK cells demonstrated that
glucagon can stimulate the intracellular accumulation
of cAMP and a transient increase in intracellular
w xcalcium levels 13 .
The existence of functional glucagon receptors on
b cells is supported by early studies demonstrating
125I-glucagon binding and activation of adenylate cy-
w xclase in immortal Syrian hamster b-cells 16 . To
 .date the expression and molecular mechanism s of
the glucagon receptor signal transduction in b cells
have not been completely elucidated. The cloning of
the glucagon receptor cDNA made it possible to
study glucagon receptor expression in b-cells using a
molecular approach. The mouse pancreatic b cell
line-b TC3 is derived from insulinomas that devel-
oped in transgenic mice expressing the SV40 large T
w xantigen under the control of the insulin promoter 17 .
b TC3 cells have low level constitutive insulin re-
lease and regulated insulin secretion in response to a
w xnumber of secretagogues 18 . In this report we
demonstrate, using Northern blot and RT-PCR analy-
sis, that the glucagon receptor mRNA is expressed in
b TC3 cells. Additionally, the dose-response curves
to glucagon for the accumulation of intracellular
cAMP and inositol phosphates in b TC3 cells were
characterized. Comparative studies using a glucagon
1w x9antagonist, des-His Glu glucagon amide, show no
effect on intracellular cAMP and inositol phosphates.
Results of these studies clearly demonstrate that the
glucagon receptors expressed in b TC3 cells transmit
intracellular signals via adenylate cyclase and phos-
pholipase C system.
2. Materials and methods
2.1. Materials
Glucagon was a kind gift from the Eli Lilly Corp.
 . 1w 9xIndianapolis, IN and des-His Glu glucagon amide
was a kind gift from Drs. C. Unson and B. Merri-
w3 x 3field. H inositol and H-cyclic AMP was purchased
 . 32from NEN-Dupont Boston, MA . P-dCTP and the
random prime DNA labelling kit were from Amer-
 .sham Corp. Arlington Heights, IL . Accell QMA
anion exchange SEP-PAK cartridges were obtained
 .from Waters Assoc. Milford, MA . Taq polymerase,
reverse transcriptase and all cell culture reagents
were purchased from Gibco Life Technology
 .Gaithersburg, MD . Forskolin was purchased from
 .Calbiochem-Behring La Jolla, CA . Meth-
 .ylisobutylxanthine IBMX , cyclic AMP dependent
protein kinase and other chemical reagents were pur-
 .chased from Sigma Chemical Corp. St. Louis., MO .
2.2. b TC3 cell culture
The b TC3 cell line was a kind gift from Dr. S.
Efrat. The cells were cultured according to Efrat et al.
w x 217 . Briefly, cells were grown on 30 mm plates in
Dulbecco’s Modified Eagle’s Medium supplemented
with 15% horse serum, 2.5% fetal bovine serum and
1% penicillin-streptomycin in 5% CO –95% O at2 2
378C. Cells were harvested by trypsinization with
0.05% trypsin and 0.53 mM EDTA. Most studies
reported used b TC3 cells from passages 35–45.
2.3. Northern blot analysis
Total RNA from b TC3 cells, mouse liver and
skeletal muscle was extracted using Tri-reagent
 .Molecular Research Center, Cinicinnati, OH ac-
cording to the manufacturer’s instructions. Approxi-
mately 30 mg of the total RNA was loaded onto an
1.2% agaroserformaldehyde gel. After electrophore-
sis the gel was transferred to a nylon membrane and
hybridized to a random prime 32P-labeled probe de-
rived from the rat glucagon receptor cDNA using
 .high strigency conditions 50% formamide, 428C .
The filter was washed using high strigency conditions
 .0.2XSSC, 0.1% SDS, 428C, 40 min and subjected
to phosphoimage analysis for visualization and quan-
titation of the results.
2.4. RT-PCR analysis
Oligonucleotide primers used in the RT-PCR reac-
tions were derived from the mouse glucagon receptor
w xcDNA sequence 15 . Primer 1 was from basepair
 Xq926 to q946 5 GATTCTGGTGGATCCTGCGT-
X.3 and primer 2 from basepair q583 to q605
 X X.5 TCTATTGGCTGCTGAAGACACG3 . Reverse
transcription reactions were carried out at 428C for 50
min using 10 mg of total RNA. Thirty cycles of PCR
reactions were carried out at 948C for 45 s, 568C for
45 s, and 728C for s. A 296 bp product was expected
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from the PCR reaction. To control for the integrity of
the RNA, b-actin RT-PCR was conducted on the
same RNA samples. The oligonucleotide primers and
RT-PCR reaction conditions were as previously de-
w xscribed 19 . The PCR products were electrophoresed
on agarose gels and identified following Southern
blot analysis and high stringency hybridization to a
randon prime 32P-labeled DNA probe specific for
either the mouse glucagon receptor or b-actin. Fol-
lowing high strigency washing the membranes were
subjected to phosphoimage analysis for visualization
and quantitation of the results.
2.5. Measurement of intracellular cAMP
Near-confluent b TC3 cells were cultured
overnight without serum before each experiment. In
the morning cells were washed with D-PBS and
incubated in modified Krebs-Ringer buffer containing
10 mM HEPES, 2.54 mM CaCl , 119 mM NaCl,2
1.19 mM KH PO , 1.19 mM MgSO , 25 mM2 4 4
 .NaHCO and 0.1% BSA pH 7.4 with 0.5 mM3
IBMX for 45 min. Different concentrations of
glucagon were added to the cells and incubated for
15 min. Cells were then washed twice with ice cold
PBS and scraped from the plates using ice-cold 0.1 N
HCl. The lysed cells were subjected to sonication and
the nuclei and unbroken cells were spun down at
1000=g for 5 min at 48C. Supernatants were har-
vested and lyophilized overnight. The cAMP content
of the lyophilized supernatant was assayed using a
w xmodified Gilman protein binding assay 20 .
2.6. Measurement of intracellular inositol phosphates
Near-confluent b TC3 cells were cultured
overnight in DMEM without inositol. In the morning
3  .the cells were labeled with H-inositol 5 mCirml
for 3 h in modified Krebs-Ringer buffer. 10 mM LiCl
was added 15 min before glucagon and then incu-
bated for an additional 30 min. The cells were washed
twice with ice cold PBS, scraped into 15% cold TCA
and centrifuged for 5 min at 1000=g at 48C. Super-
natants were then extracted four times with an equal
w3 xvolume of ether. Separation of the H inositol phos-
phates was according to the modifications of Larocca
w xet al. 21 .
3. Results
3.1. Glucagon receptor mRNA expression in b TC3
cells
Expression of the glucagon receptor in b TC3 cells
was studied by Norhtern blot and RT-PCR analyses.
Nothern blot analysis was performed using total RNA
from b TC3 cells and mouse liver to verify glucagon
receptor expression in these cells. A 1.9 kb mRNA
was detected in both b TC3 and liver using a rat
 .glucagon receptor cDNA probe Fig. 1A . The size of
the glucagon receptor mRNA detected in b TC3 cells
is approximately the same as that detected in mouse
w xand rat liver 13,15 . Densitometric analysis revealed
that the steady state levels of glucagon receptor
mRNA in b TC3 cells is approximately 3-fold less
than that detected in mouse liver. To be certain that
the mRNA detected in b TC3 cells is in fact specifi-
cally the glucagon receptor mRNA, reverse transcrip-
 .tion RT -PCR was performed on b TC3 total RNA
w xusing glucagon receptor-specific primers 15 .
Oligonucleotide primers derived from the mouse
glucagon receptor cDNA sequence were used in both
the reverse transcription and PCR reactions. Mouse
liver and muscle total RNA were used as positive and
negative controls, respectively. The RT-PCR prod-
ucts were electrophoresed and subjected to Southern
blot analysis and high stringency hybridization with a
murine glucagon receptor cDNA probe. A 296 bp
glucagon receptor-specific RT-PCR product was veri-
fied in liver and b TC3 cells but not in muscle Fig.
.1B . The quality of the RNAs used in this study were
verified by performing RT-PCR analysis using oligo-
nucleotide primers specific for b-actin on the same
RNA used to study glucagon receptor expression
 .Fig. 1B . The results of Northern blot and RT-PCR
analyses clearly demonstrate that the glucagon recep-
tor is expressed in b TC3 cells.
3.2. Intracellular cAMP production in response to
glucagon
To examine the action of glucagon on intracellular
cAMP accumulation in b TC3 cells, we incubated the
cells with varying concentrations of glucagon 500
.pM to 250 nM in the presence of 0.5 mM of IBMX
and in the absence of glucose. Fig. 2 diagrams the
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changes in intracellular cAMP levels over the range
of glucagon doses. Glucagon induces a dose-depen-
dent increase in intracellular cAMP accumulation in
b TC3 cells. Increased intracellular cAMP accumula-
tion can be observed in cells incubated with as little
as 5 nM glucagon, however, a 4.3-fold increase in
intracellular cAMP levels is noted in cells treated
with 100 nM glucagon. Half maximal accumulation
of intracellular cAMP is observed in cells incubated
with approximately 20 nM glucagon.
 .Fig. 1. Glucagon receptor expression in b TC3 cells. A : North-
ern Blot analysis of Glucagon receptor mRNA in b TC3 cells.
Approx. 30 mg of the total RNA prepared from b TC3 cells and
mouse liver was loaded onto an agaroserformaldehyde gel and
subjected to Northern blot analysis. The glucagon receptor mRNA
was detected following high stringency hybridization to the insert
from the rat glucagon receptor cDNA. The integrity of the RNA
used was determined by ethidium bromide staining of the gel.
 .B . RT-PCR analysis of GR mRNA in b TC3 cells. Reverse
 .transcription-PCR RT-PCR was performed on 5 mg of total
RNA extracted from b TC3 cells, mouse liver and mouse skeletal
muscle using oligonucleotide primers specific for glucagon recep-
tor and b-actin. The RT-PCR products were identified by South-
ern blot analysis using mouse glucagon receptor and b-actin
32  .specific P-labeled probes. The glucagon receptor 296 bp and
 .b-actin specific 243 bp products were identified following
phosphoimage analysis. Skeletal muscle is included as a negative
control tissue that deos not express glucagon receptor mRNA.
Fig. 2. Dose response curve of the effect of glucagon on intra-
cellular accumulation of cAMP in b TC3 cells. b TC3 cells were
incubated with 0.5 mM IBMX for 30 min at 378C in the presence
of the indicated glucagon concentrations. The accumulation of
cAMP was determined as described. Values are the mean"S.E.M.
for three replicate samples from one typical experiment using an
average of 3=10y6 cells per plate. When the error bar is not
shown, it is so small that it falls into the symbol. The data shown
are representative of three separate experiments.
The influence of the glucagon analogue des-
1w 9xHis Glu glucagon amide on intracellular cAMP ac-
cumulation in b TC3 cells was also examined. Des-
1w 9xHis Glu glucagon amide is a well established antag-
onist of glucagon which has been shown to bind to
rat hepatocytes as well as native glucagon but has no
glucagon-associated biological effect on these cells
w x22 . Similar to that noted previously in hepatocytes,
no increase in intracellular cAMP levels is observed
in b TC3 cells treated with 100 pM, 1 nM or 100 nM
1w 9x  .des-His Glu glucagon amide Fig. 3 .
3.3. Intracellular inositol phosphates production in
response to glucagon
The treatment of b TC3 cells with 1 nM glucagon
results an intracellular increase in the inositol phos-
phates. The chromatographic separation of the
w3 x  .H inositol phosphates IPs revealed that glucagon
treatment results principally in an increase in the
w3 x  .accumulation of H inositol 1-phosphate IP . How-
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1w 9xFig. 3. Effect of the glucagon analogue des-His Glu glucagon
amide on the accumulation of intracellular cAMP in b TC3 cells.
The experiments were carried out as described in Fig. 2 using 0,
1w 9x100 pM, 10 nM or 100 nM of des-His Glu glucagon amide.
Values are the mean"S.E.M. for triplicate samples from one
typical experiment using an average of 3=10y6 cells per plate.
The data shown are representative of three separate experiments.
Differences between groups were determined by two tailed Stu-
dent’s t test.
ever, a glucagon-dependent increase in levels of
w3 x w3 xH inositol 1,4-bisphosphate, H inositol 1,4,5-tri-
 .phosphate IP3 was also observed. In addition, it
was observed a glucagon-dependent increase in a
w3 xmixture of IPs that contained H inositol 1,3,4,6-te-
 . w3 xtrakisphosphate IP , H inositol 1,3,4,5,6-pento-4
Fig. 4. The effect of glucagon on the intracellular accumulation
 .of inositol phosphates in b TC3 cells. A Elution pattern of
inositol phosphates in a typical run following the glucagon
w3 xstimulation of b TC3 cells prelabeled with H inositol. b TC3
w3 x  .cells were labelled with H inositol 5 mCirml for 3 h, washed,
and stimulsated with 10y9 M glucagon for 30 min in the
presence of 10 mM Liq. Main graph: Labeled inositol phosphates
were chromatographed on Accell QMA Sep-Pak cartridge, with a
discontinuous gradient of ammonium formaterformic acid in 5
mM sodium borate. The inset shows in greater detail the distribu-
tion of radioactivity in fraction 11–21. O-O: control, v-v:
 .glucagon. B Dose response curve of the effect of glucagon on
the intracellular accumulation of inositol phosphates in b TC3
3  .cells. b TC3 cells were labeled with H-inositol 5mCirml for 3
h at 378C followed by the addition of the indicated concentrations
of glucagon and incubated for 30 min. The accumulation of
intracellular IPs was determined as described above. Values are
the mean"S.E.M. from four replicate samples from one typical
experiment using an average of 8=10y5 cells per plate. The
same experiment was repeated three times with similar results.
 . w3 xkisphosphate IP and H inositol hexakisphosphate5
 .  .IP Fig. 4A .6
The intracellular accumulation of inositol phos-
phates in response to varying concentrations of
glucagon was examined. The accumulation of intra-
cellular IPs in the presence of 10 mM LiCl is clearly
 .biphasic in the function of glucagon Fig. 4B . The
stimulatory phase of the response begins at 100 pM
glucagon and reaches a maximal response level in
cells treated with 1–5 nM glucagon. An approx.
2-fold increase in the accumulation of inositol phos-
phates is observed in the presence of 1–5 nM
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1w 9xFig. 5. Effect of the glucagon analogue des-His Glu Glucagon
amide on the intracellular accumulation of inositol phosphates in
b TC3 cells. The experiments were carried out as described in
Fig. 4B using 0, 100 pM, 10 nM and 100 nM of des-
1w 9xHis Glu glucagon amide. The data shown are the average"
S.E.M. of three replicates from one experiment using an average
of 3=106 cellsrplate. The same experiment was repeated three
times with similar results. Differences between groups were
determined by two tailed Student’s t test.
glucagon. The EC of the stimulatory phase is ap-50
proximately 100 pM. Inhibition of the accumulation
of inositol phosphates is noted in cells incubated with
glucagon concentrations above 5 nM. In b TC3 cells
incubated with 1mM glucagon, the accumulation of
intracellular IPs decreased to approx. 30% that of the
untreated cells. The EC for the inhibitory phase of50
the glucagon response is approx. 50 nM.
We also studied the accumulation of intracellular
inositol phosphates using the glucagon analogue des-
1w 9xHis Glu glucagon amide. IPs accumulation is not
modified in b TC3 cells treated with 100 pM, 1 nM
1w 9x  .or 100 nM of des-His Glu glucagon amide Fig. 5 .
4. Discussion
Glucagon has been shown to be an insulin secreta-
w xgogue 3 . We therefore set out to study expression of
the glucagon receptor and glucagon-stimulated sig-
nalling pathways in pancreatic b cells using the
b TC3 cell line. b TC3 cells have been used as a
model b cell system to study glucose sensing and
insulin secretion in response to a number of stimuli
w x18 . In this study we demonstrate that the glucagon
receptor mRNA is expressed in b TC3 cells and it is
functional in transmitting intracellular signals through
both the adenylate cyclase and phospholipase C sec-
ond messenger systems. These results shed new light
on the intracellular mechanisms of glucagon-stimu-
lated insulin secretion.
Results of both Northern blot and RT-PCR analy-
ses indicated the presence of only one type of
glucagon receptor in b TC3 cells. The glucagon re-
ceptor mRNA detected in b TC3 cells is the same
size as that observed in the mouse liver but it is of
relatively lower abundance. These results cannot ex-
clude the possibility that two species of glucagon
receptor mRNA are expressed in b TC3 cells. An
alternatively spliced glucagon receptor mRNA ap-
proximately the same size as the known glucagon
receptor mRNA would not have been distinguished
by Northern blot or RT-PCR analysis if the oligo-
nucleotide primers chosen could not distinguish the
difference between the two receptor mRNAs. Addi-
tionally, the glucagon receptor protein may undergo
post-translational modifications which result in two
populations of receptors that couple to different G
proteins. Ligand binding affinity analysis and chro-
matographic purification of glucagon receptors from
rat hepatocytes have suggested that there may be two
w xpopulations of glucagon receptors 9–12 .
Early studies of Birnbaumer and co-workers exam-
ined the glucagon receptors expressed in Syrian ham-
w xster pancreatic b cell tumors 16 . Crude membrane
fractions were shown to contain specific 125I-gluca-
w xgon binding sites 16 . Glucagon-stimulated cAMP
production displayed a half maximal activation at 3
nM. An approximate 2-fold increase in cAMP was
detected under the above conditions. In the present
study, we demonstrated that b TC3 cells exhibit a
4.3-fold increase in the accumulation of intracellular
cAMP upon glucagon stimulation. The EC for50
glucagon-dependent cAMP formation is approxi-
mately 20 nM. Further characterization of the
glucagon receptor in b TC3 cells using the glucagon
1w 9xanalogue-des-His Glu glucagon amide were per-
formed. This analogue has been shown to have a
binding affinity similar to native glucagon in rat
w xhepatocyte membranes 22 . b TC3 cells incubated
1w 9xwith des-His Glu glucagon amide exhibited no
change in intracellular cAMP accumulation. These
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results demonstrate that the glucagon receptor ex-
pressed in b TC3 cells couples with adenylate cy-
clase.
Additionally, our studies demonstrate that the
glucagon receptor expressed in b TC3 cells also cou-
ples to phospholipase C. The glucagon-stimulated
accumulation of IPs is biphasic. The maximal stimu-
lation of accumulation of IPs was observed at lower
concentrations than the maximal cAMP response de-
tected. Our results showed that the increase in the
w3 xaccumulation of H IPs were primarily caused by
the accumulation of IP. In addition, a glucagon de-
pendent increase in IP was also observed. The in-3
crease in the level of IP indicated that glucagon3
stimulation resulted in an increase in the hydrolysis
of PIP . However, we cannot rule out the possibility2
that glucagon treatment also elicited the hydrolysis of
PIP and PI. Similar pattern of glucagon-stimulated
intracellular inositol phosphates and cAMP accumu-
w xlations have been observed in rat hepatocytes 4–8 .
To further characterize the phospholipase C mediated
glucagon response, the b TC3 cells were incubated
1w 9xwith des-His Glu glucagon amide. Earlier studies
showed that this analogue does not induce the accu-
mulation of inositol phosphates or cAMP in rat hepa-
w xtocytes 22 . Similarly, no significant change in the
accumulation of intracellular inositol phosphates was
1w 9xobserved in des-His Glu glucagon amide-treated
cells.
The molecular mechanism underlying the induc-
tion of two different signal transduction pathways by
glucagon is currently unknown. Nevertheless, the
glucagon receptor is not the only receptor that has
been shown to induce the accumulation of both cAMP
and IPs in response to ligand binding. To date, the
mammalian PTHrPTHrP and LH receptors are other
seven transmembrane domain receptors able to cou-
ple to both phosphoinositol breakdown and cAMP
w xaccumulation 23,24 . However, the biphasic nature
of inositol phosphate accumulation in response to
glucagon is unique. Earlier studies on rat hepatocyte
membranes suggested that the activation of phospho-
lipase C by glucagon may result in the inhibition of
w xglucagon-stimulated adenylate cyclase activity 4,5 .
Two functionally different subpopulations of glucagon
receptors was postulated based upon the two different
w xsignalling features noted in rat hepatocytes 25 . When
the rat liver glucagon receptor cDNA was transfected
into BHK cells, an increase in intracellular cAMP
accumulation and calcium concentration was ob-
w xserved 13 . Although the accumulation of intra-
cellular inositol phosphates in BHK cells transfected
with the glucagon receptor cDNA was not measured
w 2qxit was concluded that the glucagon-induced Ca i
increase was due to the activation of the phopholi-
w xpase C second messenger system 13 .
The glucagon receptor in b TC3 cells activates
similar intracellular signalling pathways to those ob-
served in hepatocytes. Glucagon stimulates hepatic
glucose production by inducing glycogen breakdown
w xand gluconeogenesis 2 . Since glucagon has very
different biologic effects on hepatocytes and pancre-
atic b-cells, it is important to explore the regulatory
features of each. The physiologic importance of the
glucagon-stimulated intracellular accumulation of in-
ositol phosphates and cAMP in b TC3 cells remains
to be explained. Future studies will examine the
above signal transduction features of the glucagon
 .receptor s in b TC3 cells in the presence of glucose
and the insulin secretory response to different con-
centrations of glucagon.
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